Ofer Toledano
Seminars
Wednesday 19th November 2025
Panel Discussion: Can Topical and Systemic Therapies Each Find Their Place in the Future of Dermatology Drug Development?
4:30 pm
- How should we balance the clinical and commercial drivers behind topical and systemic innovation, especially as realworld prescribing habits continue to favor topicals? How are these approaches viewed from the patient, regulator and investor perspective?
- Which factors, including disease severity, body surface area, and treatment setting, best guide whether a topical, systemic, or combination approach is most appropriate? How can we best utilize both routes to ensure there is a treatment fit for everyone?
- How are both approaches evolving to better meet patient needs, from systemics tackling severe or widespread disease to topicals aiming for convenience, safety, or even disease modification?
- What are the key trade-offs between topical and systemic treatments in terms of patient adherence, cost, quality of life, and long-term disease control and how can trials be designed to reflect this?
Thursday 20th November 2025
Advancing Topical Therapies for Rare Dermatologic Diseases for Safer, More Targeted Treatment
2:30 pm
- Enabling topical delivery of novel molecules, aiming to reduce systemic exposure and adverse events in rare skin conditions
- Understanding the different regulatory and funding approaches required for the rare space
- SGT-610, currently in Phase 3 for Gorlin Syndrome, offers an alternative to systemic hedgehog inhibitors with a potentially improved safety profile
- SGT-210, in Phase 1 for Darier disease and other rare disorders, represents a new approach to targeting keratin mutations through localized therapy
